RALLYBIO CORPORATION Debt Securities, Available-for-sale, Allowance for Credit Loss
RALLYBIO CORPORATION (RLYB) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2023-11-09
- 2023-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2023-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2022-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |